Using Everolimus to Treat Kidney Transplant Patients with Unique Rejection Issues

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of Everolimus, an mTOR inhibitor, in kidney transplant patients who exhibit a specific type of rejection characterized by missing self-induced NK cell activity. The research aims to address the limitations of current understanding of organ rejection, which traditionally focuses on the adaptive immune response. By targeting innate immune mechanisms, the study seeks to improve graft function and patient outcomes in those with microvascular inflammation and mild chronic lesions without donor-specific antibodies. The approach is based on previous findings that suggest mTOR inhibitors can prevent this novel rejection type.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged \> 18 years
* Kidney transplanted patient
* Having microvascular inflammation lesion on his graft biopsy associated to mild chronic lesions
* In absence of donor specific antibodies
* In presence of a missing self

Exclusion Criteria:

* Proteinuria/urinary creatinin \> 100 mg/mmol
* Antecedent of poor tolerance or hypersensibility to everolimus or sirolimus
* Severe chronic lesions
* Presence of donor specific antibodies

Where it's running

• Service de transplantation, néphrologie et immunologie clinique, Hôpital Edouard Herriot (HCL)
  Lyon, France Recruiting

Study contacts

• Study coordinator: Alice KOENIG, MD
• Email: alice.koenig@chu-lyon.fr
• Phone: 472110178

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inducing immunological tolerance in kidney transplant patients using stem cell infusion

  This study is testing whether giving stem cells from the same donor to kidney transplant patients can help them stop taking their immunosuppressive medications safely.

  Recruiting Phase 1 University of California, Los Angeles · Los Angeles, California · NCT05525507

• Treating BK Virus Infections in Kidney Transplant Recipients

  This study is testing if changing the way we manage immune suppression and giving a special treatment can help kidney transplant patients with BK virus infections feel better and keep their transplants healthy.

  Recruiting at 13 sites Phase 3 The University of Queensland · Canberra, Australian Capital Territory and 12 other locations · NCT05325008

• Investigating tacrolimus metabolism in kidney transplant patients

  This study looks at how kidney transplant patients process a medication called tacrolimus over four years to see if it affects their kidney health and how genetics might play a role.

  Recruiting University Hospital, Grenoble · Grenoble, Auvergne-Rhône-Alpes and 1 other locations · NCT04526431

• Belimumab to mobilize memory B cells to help delistings for highly sensitized kidney transplant candidates

  A short belimumab course is being tested to see if it can reveal memory B cells that target donor HLAs, helping to decide which donors to exclude and potentially speed up getting a transplant for highly sensitized patients.

  Recruiting Phase 2 Leiden University Medical Center · Leiden · NCT07539857

• Frexalimab versus tacrolimus to prevent kidney transplant rejection

  This trial will test whether frexalimab injections given for up to five years work as well and are as safe as tacrolimus capsules at preventing rejection in adults getting their first kidney transplant who have low-to-moderate immune risk.

  Recruiting at 73 sites Phase 2/3 Sanofi · San Francisco, California and 72 other locations · NCT07412470

• Platelet aggregation for diagnosing acute kidney transplant rejection

  This study will test whether changes in platelet activation measured from blood can help detect acute rejection in adult kidney transplant recipients.

  Recruiting University Hospital, Martin · Martin · NCT07275541

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.